



Novartis India Limited
Registered Office:
Inspire BKC
7th Floor
Bandra Kurla Complex
Bandra (East)
Mumbai – 400 051
Maharashtra, India
Tel +91 22 50243000
Fax +91 22 50243010
Email: india.investors@novartis.com
CIN No. L24200MH1947PLC006104
Website: www.novartis.in

October 27, 2023

To,
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 500672

Dear Sir/ Madam,

Sub.: Outcome of the Meeting of the Board of Directors of Novartis India Limited ('the Company') held today i.e. Friday, October 27, 2023

In continuation to our intimation dated September 30, 2023 and pursuant to Regulations 30 (read with Para A of Part A of Schedule III) and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('**SEBI Listing Regulations**') read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 ('**SEBI Circular**'), wherever applicable, we hereby inform that the Board of Directors of the Company at its Meeting held today i.e. October 27, 2023, *inter-alia*, have considered and approved the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2023, as recommended by the Audit Committee of the Company.

The said Meeting commenced at 01:20 P.M. (IST) and concluded at 03:00 P.M. (IST)

In terms of Regulation 33 of SEBI Listing Regulations, please find enclosed herewith:

- a) the Unaudited Financial Results for the second quarter and half year ended September 30, 2023; and
- b) Limited Review Report dated October 27, 2023, issued by the Statutory Auditors of the Company with respect to the Unaudited Financial Results and taken on record by the Board of the Company

The above is for your information and the same is also available on the Company's website i.e. www.novartis.in

Thanking you

Yours Sincerely,

For Novartis India Limited

Malpani Nikhil Digitally signed by Malpani Nikhil
DN: dc=corp, dc=novartis, ou=people, ou=CS,
serialNumber=3079258, cn=Malpani Nikhil
Date: 2023.10.27 15:03:17 +0530

Nikhil Malpani
Company Secretary and Compliance Officer

Encl: as above

Novartis India Limited							
Regd. off: Inspire - BKC, 7th Floor, Bandra Kurla Complex, Bandra East, Mumbai 400051. www.novartis.in, CIN:L24200MH1947PLC006104							
(₹ in million)							
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED 30.09.2023							
Sr. No.	Particulars	3 months ended	3 months ended	3 months ended	6 months ended	6 months ended	Year ended
		30.09.2023 (Unaudited)	30.06.2023 (Unaudited)	30.09.2022 (Unaudited)	30.09.2023 (Unaudited)	30.09.2022 (Unaudited)	31.03.2023 (Audited)
1.	Revenue from Operations	787.6	906.0	1,015.2	1,693.6	2,224.4	3,787.4
	Other Income (Refer note 6)	168.8	124.2	68.6	293.0	333.8	581.1
	Total Income	956.4	1,030.2	1,083.8	1,986.6	2,558.2	4,368.5
2.	Expenses						
	(a) Purchases of Stock-in-Trade	444.6	399.3	524.5	843.9	953.0	1,993.4
	(b) Changes in Inventories of Stock-in-Trade	2.6	128.1	(14.2)	130.7	131.8	23.5
	(c) Employee Benefits Expense	53.7	61.8	115.1	115.5	206.7	356.4
	(d) Finance Costs	7.1	4.6	4.9	11.7	9.9	17.5
	(e) Depreciation Expense	6.5	15.6	13.8	22.1	26.8	60.6
	(f) Impairment Loss on Receivables	-	-	1.5	-	2.9	3.7
	(g) Other Expenses	117.6	143.1	225.1	260.7	448.8	759.6
	Total Expenses	632.1	752.5	870.7	1,384.6	1,779.9	3,214.7
3.	Profit Before Tax	324.3	277.7	213.1	602.0	778.3	1,153.8
4.	Tax Expense/(Credit)						
	Current Tax (Refer Note 7)	79.6	76.1	51.3	155.7	35.7	16.8
	Deferred Tax	7.9	(1.0)	(21.7)	6.9	35.3	103.4
	Total Tax Expense	87.5	75.1	29.6	162.6	71.0	120.2
5.	Profit for the Period / Year	236.8	202.6	183.5	439.4	707.3	1,033.6
6.	Other Comprehensive Income	-	-	-	-	-	31.1
	- Items that will not be reclassified to profit or loss						
	Remeasurements gain on the defined benefit plans	-	-	-	-	-	41.5
	Income tax relating to these items	-	-	-	-	-	(10.4)
7.	Total Comprehensive Income for the Period / Year	236.8	202.6	183.5	439.4	707.3	1,064.7
8.	Paid-up Equity Share Capital (Face Value ₹ 5 each)	123.4	123.4	123.4	123.4	123.4	123.4
9.	Other Equity						7,633.2
10.	Earnings Per Share (in ₹) (Basic & Diluted)- (of ₹ 5 each) (*not annualized)	9.59 *	8.21 *	7.43 *	17.80 *	28.64 *	41.86

Notes:

1. Statement of Assets and Liabilities

Particulars	As at	As at
	30.09.2023 (Unaudited)	31.03.2023 (Audited)
A Assets		
Non-Current Assets		
Property, Plant and Equipments	12.1	18.5
Right-of-Use Assets	66.2	174.0
Financial Assets		
(i) Other Financial Assets	27.6	25.4
Deferred Tax Assets (Net)	151.1	158.0
Other Tax Assets (Net)	1,607.8	1,789.2
Other Non-Current Assets	873.2	891.0
Total Non-Current assets	2,738.0	3,056.1
Current Assets		
Inventories	415.6	547.2
Financial Assets		
(i) Trade Receivables	438.2	361.6
(ii) Cash and Cash Equivalents	398.0	194.2
(iii) Bank Balances other than (ii) above	4,502.7	5,365.2
(iv) Other Financial Assets	108.7	138.7
Other Current Assets	104.5	166.0
	5,967.7	6,772.9
Assets held for sale	-	0.4
Total Current assets	5,967.7	6,773.3
TOTAL ASSETS	8,705.7	9,829.4
B Equity and Liabilities		
Equity		
Equity Share Capital	123.4	123.4
Other Equity	6,899.4	7,633.2
Total Equity	7,022.8	7,756.6
Liabilities		
Non-Current Liabilities		
Financial Liabilities		
(i) Lease Liabilities	64.3	173.9
(ii) Other Financial Liabilities	2.9	77.9
Provisions	224.4	226.1
Total Non-Current Liabilities	291.6	477.9
Current Liabilities		
Financial Liabilities		
(i) Lease Liabilities	18.3	41.2
(ii) Trade Payables		
- total outstanding dues of micro and small enterprises	5.4	12.3
- total outstanding dues of creditors other than micro and small enterprises	430.3	584.4
(iii) Other Financial Liabilities	269.9	301.3
Other Current Liabilities	27.0	37.8
Provisions	523.0	557.1
Current Tax Liabilities (Net)	117.4	60.8
Total Current Liabilities	1,391.3	1,594.9
TOTAL EQUITY AND LIABILITIES	8,705.7	9,829.4



2 Statement of Cash Flows:

(₹ in million)

Particulars	6 months ended September 30, 2023 (Unaudited)	6 months ended September 30, 2022 (Unaudited)
A. A. Cash flow from operating activities		
Profit before tax	602.0	778.3
Adjustments for -		
Depreciation Expense	22.1	26.8
Share Based Payments	0.9	2.7
(Gain) on Sale/Disposal of Property held for sale	(31.4)	-
Interest Income	(231.3)	(328.2)
Unwinding of discount on security deposits	(0.8)	(0.7)
Finance Costs	11.7	9.9
Gain on derecognition of lease liability and Right-of-Use Assets	(26.2)	-
(Gain) on sale of Property, Plant and Equipment (Net)	-	(1.7)
Unrealised loss on Foreign currency translations (Net)	0.7	1.6
Credit Balances Written-Back	(1.4)	(1.5)
Impairment loss on receivables	-	2.9
Provision for deposits/advances (net)	(1.5)	9.4
Operating cash flows before working capital changes	344.8	499.5
Movement in operating assets and liabilities		
(Increase) Trade Receivables	(76.6)	(111.0)
Decrease Inventories	131.6	131.8
Decrease Non-current Financial Assets Loan	-	5.8
Decrease Non-current Financial Assets Others	0.8	5.7
(Increase) Current Financial Assets Loan	-	(0.5)
Decrease Current Financial Assets Others	20.2	46.3
Decrease Other Non-Current Assets	17.8	58.4
Decrease Other Current Assets	62.1	17.6
(Decrease) Trade Payables	(160.3)	(164.4)
(Decrease) Provisions	(35.8)	(211.1)
(Decrease) Other Current Liabilities	(10.8)	(51.8)
(Decrease)/Increase Non-current Financial Liabilities	(75.0)	74.3
(Decrease)/Increase Current Financial Liabilities	(28.9)	234.3
Cash generated from operating activities	189.9	534.9
Income Tax Paid (Net)	135.4	129.1
Net Cash generated from operating activities	325.3	664.0
B. Cash flow from investing activities		
Payments for Property, Plant and Equipment	-	(39.6)
Proceeds from disposal of Property, Plant and Equipment	-	41.7
Proceeds from disposal of Property Held for Sale	31.8	-
Interest received	187.7	84.5
Fixed deposits placed during the year	(4,890.0)	(8,010.0)
Fixed deposits receipts during the year	5,747.9	6,029.4
Net cash generated/(used in) from investing activities	1,077.4	(1,894.0)
C. Cash flow from financing activities		
Lease payments	(26.1)	(30.1)
Finance cost paid	-	(0.3)
Dividends paid	(1,172.8)	(246.9)
Net cash (used in) financing activities	(1,198.9)	(277.3)
Net Increase/(Decrease) in Cash and Cash Equivalents	203.8	(1,507.3)
Cash and Cash Equivalents - At the beginning of the period	194.2	1,583.5
Cash and Cash Equivalents - At the end of the period	398.0	76.2

- 3 This statement of unaudited financial results for the quarter and six months ended 30 September, 2023 (the 'Statement') has been reviewed by the Audit Committee at its meeting held on 27 October, 2023 and approved at the meeting of the Board of Directors held on that date and has been subjected to limited review by the statutory auditors of the Company.
- 4 This Statement has been prepared in accordance with Indian Accounting Standards notified under the Companies (Indian Accounting Standards) Rules, 2015 notified under section 133 of the Companies Act, 2013 and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time).
- 5 The Company has a single business segment namely 'Pharmaceuticals Business'.
- 6 Other income includes interest on income tax refund for the year ended 31 March 2023 aggregating to ₹ 267.5 million, for six months ended 30 September 2023 and 30 September 2022 ₹ 53.1 million and ₹ 217.0 million respectively and for the quarters ended 30 September 2023, 30 June 2023 and 30 September 2022 ₹ 46.7 million, ₹ 6.4 million and ₹ 1.2 million respectively.
- Other income for the quarter ended 30 June 2023 and six months ended 30 September 2023, includes gain on derecognition of lease liability and Right-of-Use assets ₹ 26.2 million.
- Other income for the quarter and six months ended 30 September 2023 and year ended 31 March 2023 includes profit on disposal of assets held for sale ₹ 31.4 million and ₹ 26.5 million respectively.
- 7 Current tax for the year ended 31 March, 2023 includes tax adjustments for earlier years of income of ₹ 194.0 million, for six month ended 30 September 2023 and 30 September 2022 expense of ₹ 0.4 million and income of ₹ 143.1 million respectively and for the quarters ended 30 September 2023, 30 June 2023 and 30 September 2022 expense of ₹ 0.3 million, expense of ₹ 0.1 million and income of ₹ 37.5 million respectively.

By Order of the Board

Rajay Murdeshwar
Vice Chairman and Managing Director
DIN:01481811
Mumbai, 27 October, 2023



Limited Review Report on unaudited financial results of Novartis India Limited for the quarter ended 30 September 2023 and year to date results for the period from 01 April 2023 to 30 September 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**To the Board of Directors of Novartis India Limited**

1. We have reviewed the accompanying Statement of unaudited financial results of Novartis India Limited (hereinafter referred to as "the Company") for the quarter ended 30 September 2023 and year to date results for the period from 01 April 2023 to 30 September 2023 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

**Maulik Jhaveri**

Partner

Mumbai

27 October 2023

Membership No.: 116008

UDIN:23116008BGYPXH8847